Clinical Trials Directory

Trials / Unknown

UnknownNCT03221231

N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
75 (estimated)
Sponsor
Universitair Ziekenhuis Brussel · Academic / Other
Sex
Male
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

This study investigates the effects of repeated NAC administration on glutamate concentrations in the anterior cingulate cortex (ACC), on neurocognitive functioning, and on neuro-inflammatory parameters in adult cannabis-dependent individuals.

Conditions

Interventions

TypeNameDescription
DRUGN-acetylcysteine1200 mg/day, twice daily, N-acetylcysteine
DRUGPlacebo Oral Tablettwice daily, placebo
OTHERMagnetic Resonance Imaging
OTHERNeurocognitive measures
OTHERNeuro-inflammatory measures

Timeline

Start date
2016-05-15
Primary completion
2022-02-01
Completion
2023-02-01
First posted
2017-07-18
Last updated
2020-12-08

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT03221231. Inclusion in this directory is not an endorsement.